Matches in Wikidata for { <http://www.wikidata.org/entity/Q92721948> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q92721948 description "2019 թվականի հունիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q92721948 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92721948 description "scientific article published on 11 June 2019" @default.
- Q92721948 description "wetenschappelijk artikel" @default.
- Q92721948 description "наукова стаття, опублікована 11 червня 2019" @default.
- Q92721948 name "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 name "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 type Item @default.
- Q92721948 label "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 label "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 prefLabel "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 prefLabel "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 P1433 Q92721948-011F668D-6BA7-4826-B6D7-4AB1057655A8 @default.
- Q92721948 P1476 Q92721948-55F4B315-063E-410C-A58C-AE9FC08BD289 @default.
- Q92721948 P2093 Q92721948-01B079CB-4B67-455B-BF9A-1F32CA1B7A8E @default.
- Q92721948 P2093 Q92721948-29F539D5-7E50-4773-9754-F82496EE5702 @default.
- Q92721948 P2093 Q92721948-384776DE-15D2-4752-AF55-65DA64334933 @default.
- Q92721948 P2093 Q92721948-385EF5FF-7FD6-442D-9F69-7468193AEBB5 @default.
- Q92721948 P2093 Q92721948-3887C6D4-E3C0-42F2-91A7-88CF992C16C0 @default.
- Q92721948 P2093 Q92721948-388B4C7B-604A-4D93-AE8A-4082B31F6F0A @default.
- Q92721948 P2093 Q92721948-3CACEAB0-9D6C-4012-BEF4-E9368BF4AFFD @default.
- Q92721948 P2093 Q92721948-45CC7FF1-3C67-453A-A7D3-52E4D0EEE68F @default.
- Q92721948 P2093 Q92721948-533861D7-B1FD-44B8-815B-A9226F8D6615 @default.
- Q92721948 P2093 Q92721948-5500A2A5-0EA7-4126-A55B-54EFBEF959A3 @default.
- Q92721948 P2093 Q92721948-55A4D038-FD5D-44A5-BEA4-90538C09C034 @default.
- Q92721948 P2093 Q92721948-5861248B-C27D-4B08-B25E-504CD675E85C @default.
- Q92721948 P2093 Q92721948-5A31B60F-5F1A-479B-AE91-B8816EC9BBD5 @default.
- Q92721948 P2093 Q92721948-61E5A95D-4257-4017-9690-34FDF9F203CA @default.
- Q92721948 P2093 Q92721948-7532B0E5-962A-4A06-B64C-1D5FCA7AD47C @default.
- Q92721948 P2093 Q92721948-75990BB2-2264-4E1E-B949-6A84C8D77284 @default.
- Q92721948 P2093 Q92721948-7A809C4A-118C-4A79-8EE7-117BCA000FFE @default.
- Q92721948 P2093 Q92721948-94DF2508-9E02-41DE-AA09-A0D0728E5288 @default.
- Q92721948 P2093 Q92721948-99EF6A23-686D-4116-929F-2D01745C0D43 @default.
- Q92721948 P2093 Q92721948-A1014073-6005-4BF1-8A9C-16318DD07126 @default.
- Q92721948 P2093 Q92721948-F0B70C96-36E6-4689-A7B8-369DA02F1941 @default.
- Q92721948 P304 Q92721948-FD9079E5-B3D6-4EC9-81E1-FD1347629C55 @default.
- Q92721948 P31 Q92721948-8FBAE1F6-FB80-4EDE-992C-9754BC608090 @default.
- Q92721948 P356 Q92721948-88594903-42AD-419F-B644-42057727712A @default.
- Q92721948 P478 Q92721948-A9A9750B-9CE7-4ECF-A456-F6AE16A09827 @default.
- Q92721948 P577 Q92721948-5DCB9318-9DF1-4D32-A3D3-647528A59589 @default.
- Q92721948 P698 Q92721948-581501D5-69A8-466E-9AAB-FCF21FFE5B2D @default.
- Q92721948 P921 Q92721948-5686578F-018C-4E01-BD36-647F1E1452BE @default.
- Q92721948 P356 J.EJCA.2019.05.008 @default.
- Q92721948 P698 31195357 @default.
- Q92721948 P1433 Q332260 @default.
- Q92721948 P1476 "Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial" @default.
- Q92721948 P2093 "Eduardo Richardet" @default.
- Q92721948 P2093 "Fabio Andre Franke" @default.
- Q92721948 P2093 "Faith E Nathan" @default.
- Q92721948 P2093 "Fiona Taylor" @default.
- Q92721948 P2093 "John R Penrod" @default.
- Q92721948 P2093 "Judith Raimbourg" @default.
- Q92721948 P2093 "Julie Brahmer" @default.
- Q92721948 P2093 "Ki Hyeong Lee" @default.
- Q92721948 P2093 "Krzysztof Lesniewski-Kmak" @default.
- Q92721948 P2093 "Kynan Feeney" @default.
- Q92721948 P2093 "Makoto Nishio" @default.
- Q92721948 P2093 "Mariano Provencio" @default.
- Q92721948 P2093 "Martin Reck" @default.
- Q92721948 P2093 "Michael DeRosa" @default.
- Q92721948 P2093 "Michael Schenker" @default.
- Q92721948 P2093 "Prabhu Bhagavatheeswaran" @default.
- Q92721948 P2093 "Rachael Lawrance" @default.
- Q92721948 P2093 "Randeep Sangha" @default.
- Q92721948 P2093 "Romain Corre" @default.
- Q92721948 P2093 "Samreen Ahmed" @default.
- Q92721948 P2093 "Yong Yuan" @default.
- Q92721948 P304 "137-147" @default.
- Q92721948 P31 Q13442814 @default.
- Q92721948 P356 "10.1016/J.EJCA.2019.05.008" @default.
- Q92721948 P478 "116" @default.
- Q92721948 P577 "2019-06-11T00:00:00Z" @default.
- Q92721948 P698 "31195357" @default.
- Q92721948 P921 Q42824827 @default.